1. Novartis. Novartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer. Novartis. Basel: Massachusetts Medical Society 2022. https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-pluvicto-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer. Accessed 2023 Apr 11
2. Hosono M, Ikebuchi H, Nakamura Y, Nakamura N, Yamada T, Yanagida S, et al. Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy. Ann Nucl Med. 2018;32:217–35.
3. Kusakabe K, Yokoyama K, Ito K, Shibuya H, Kinuya S, Ito M, et al. Thyroid remnant ablation using 1,110 MBq of I-131 after total thyroidectomy: regulatory considerations on release of patients after unsealed radioiodine therapy. Ann Nucl Med. 2012;26:370–8.
4. World Health Organization. Cancer population fact sheet: World. World Health Organization 2022. https://gco.iarc.fr/today/data/factsheets/populations/908-europe-fact-s Accessed 2023 Apr 18
5. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, et al. Impact of 68Ga-PSMA-11 PET on management in patients with biochemically recurrent prostate cancer. J Nucl Med. 2017;58:1956–61.